Annual report
2370.TEDINET S100PT7B
Period2021-10-01 → 2022-09-30
Filed2022-12-15
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 92
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥634m | 2021-10-01 → 2022-09-30 | Standalone | Net sales |
| Revenue | ¥683m | 2020-10-01 → 2021-09-30 | Standalone | Net sales |
| Revenue | ¥783m | 2019-10-01 → 2020-09-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.1bn | 2018-10-01 → 2019-09-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥998m | 2017-10-01 → 2018-09-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥958m | 2017-10-01 → 2018-09-30d | Standalone | Net sales (5-year summary) |
| Operating income | −¥1.3bn | 2021-10-01 → 2022-09-30 | Standalone | Operating income |
| Operating income | −¥1.1bn | 2020-10-01 → 2021-09-30 | Standalone | Operating income |
| Ordinary income | −¥1.3bn | 2021-10-01 → 2022-09-30 | Standalone | Ordinary income |
| Ordinary income | −¥871m | 2020-10-01 → 2021-09-30 | Standalone | Ordinary income |
| Ordinary income | −¥837m | 2019-10-01 → 2020-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥995m | 2018-10-01 → 2019-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.7bn | 2017-10-01 → 2018-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.7bn | 2017-10-01 → 2018-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.2bn | 2021-10-01 → 2022-09-30 | Standalone | Income before income taxes |
| Profit before tax | −¥838m | 2020-10-01 → 2021-09-30 | Standalone | Income before income taxes |
| Net income (owners) | −¥3.0bn | 2017-10-01 → 2018-09-30d | Standalone | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥1.3bn | 2021-10-01 → 2022-09-30 | Standalone | Profit loss |
| Net income | −¥843m | 2020-10-01 → 2021-09-30 | Standalone | Profit loss |
| Net income | −¥842m | 2019-10-01 → 2020-09-30d | Standalone | Net income loss (5-year summary) |
| Net income | −¥795m | 2018-10-01 → 2019-09-30d | Standalone | Net income loss (5-year summary) |
| Net income | −¥3.1bn | 2017-10-01 → 2018-09-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥6.1bn | at 2022-09-30 | Standalone | Assets |
| Total assets | ¥5.4bn | at 2021-09-30 | Standalone | Assets |
| Total assets | ¥5.2bn | at 2020-09-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥3.1bn | at 2019-09-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥3.9bn | at 2018-09-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥3.9bn | at 2018-09-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥566m | at 2022-09-30 | Standalone | Liabilities |
| Total liabilities | ¥475m | at 2021-09-30 | Standalone | Liabilities |
| Net assets / equity | ¥5.5bn | at 2022-09-30 | Standalone | Net assets |
| Net assets / equity | ¥4.9bn | at 2021-09-30 | Standalone | Net assets |
| Net assets / equity | ¥4.8bn | at 2020-09-30d | Standalone | Net assets |
| Net assets / equity | ¥2.6bn | at 2019-09-30d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥3.3bn | at 2018-09-30d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥3.3bn | at 2018-09-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.5bn | at 2022-09-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.1bn | at 2021-09-30 | Standalone | Cash and deposits |
| Cash & equivalents | ¥4.5bn | at 2022-09-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.1bn | at 2021-09-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥3.6bn | at 2020-09-30d | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.4bn | at 2019-09-30d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥2.2bn | at 2018-09-30d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥1.2bn | 2021-10-01 → 2022-09-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥975m | 2020-10-01 → 2021-09-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥633m | 2019-10-01 → 2020-09-30d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥938m | 2018-10-01 → 2019-09-30d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥2.5bn | 2017-10-01 → 2018-09-30d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥20m | 2021-10-01 → 2022-09-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥344m | 2020-10-01 → 2021-09-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥86m | 2019-10-01 → 2020-09-30d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥50m | 2018-10-01 → 2019-09-30d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥154m | 2017-10-01 → 2018-09-30d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.6bn | 2021-10-01 → 2022-09-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2020-10-01 → 2021-09-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.8bn | 2019-10-01 → 2020-09-30d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥90m | 2018-10-01 → 2019-09-30d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2017-10-01 → 2018-09-30d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-6.33 | 2021-10-01 → 2022-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.88 | 2020-10-01 → 2021-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.19 | 2019-10-01 → 2020-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.71 | 2018-10-01 → 2019-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-26.77 | 2017-10-01 → 2018-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-27.47 | 2017-10-01 → 2018-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥26.03 | at 2022-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥27.31 | at 2021-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥29.6 | at 2020-09-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥21.1 | at 2019-09-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥27.56 | at 2018-09-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥27.03 | at 2018-09-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 90.7% | at 2022-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.8% | at 2021-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.7% | at 2020-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 82.7% | at 2019-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 82.8% | at 2018-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 82.7% | at 2018-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -24.1% | 2021-10-01 → 2022-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -17.5% | 2020-10-01 → 2021-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -23.0% | 2019-10-01 → 2020-09-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | -27.7% | 2018-10-01 → 2019-09-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | -70.0% | 2017-10-01 → 2018-09-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | -72.2% | 2017-10-01 → 2018-09-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 211,730,423 | at 2022-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 178,750,423 | at 2021-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 160,830,423 | at 2020-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 120,875,423 | at 2019-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 118,230,423 | at 2018-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 96 | at 2022-09-30 | Standalone | Number of employees |
| Employees | 83 | at 2021-09-30 | Standalone | Number of employees |
| Employees | 78 | at 2020-09-30d | Standalone | Number of employees |
| Employees | 76 | at 2019-09-30d | Standalone | Number of employees |
| Employees | 92 | at 2018-09-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2021-10-01 → 2022-09-30 | ¥13m |
| Reconciling Itemsreconciling | depreciation | 2021-10-01 → 2022-09-30 | ¥22m |
| Reconciling Itemsreconciling | segment assets | at 2022-09-30 | ¥5.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-10-01 → 2022-09-30 | −¥518m |
| Cellular And Tissue Based Product Businessreportable segment | capex | 2021-10-01 → 2022-09-30 | ¥4m |
| Cellular And Tissue Based Product Businessreportable segment | depreciation | 2021-10-01 → 2022-09-30 | ¥28m |
| Cellular And Tissue Based Product Businessreportable segment | employees | at 2022-09-30 | 19 pure |
| Cellular And Tissue Based Product Businessreportable segment | revenue | 2021-10-01 → 2022-09-30 | ¥221,000 |
| Cellular And Tissue Based Product Businessreportable segment | revenue external | 2021-10-01 → 2022-09-30 | ¥221,000 |
| Cellular And Tissue Based Product Businessreportable segment | segment assets | at 2022-09-30 | ¥147m |
| Cellular And Tissue Based Product Businessreportable segment | segment profit | 2021-10-01 → 2022-09-30 | −¥582m |
| Contracted Cell Manufacturing Businessreportable segment | capex | 2021-10-01 → 2022-09-30 | ¥60m |
| Contracted Cell Manufacturing Businessreportable segment | depreciation | 2021-10-01 → 2022-09-30 | ¥56m |
| Contracted Cell Manufacturing Businessreportable segment | employees | at 2022-09-30 | 65 pure |
| Contracted Cell Manufacturing Businessreportable segment | revenue | 2021-10-01 → 2022-09-30 | ¥633m |
| Contracted Cell Manufacturing Businessreportable segment | revenue external | 2021-10-01 → 2022-09-30 | ¥633m |
| Contracted Cell Manufacturing Businessreportable segment | segment assets | at 2022-09-30 | ¥643m |
| Contracted Cell Manufacturing Businessreportable segment | segment profit | 2021-10-01 → 2022-09-30 | −¥233m |
| —segment total | capex | 2021-10-01 → 2022-09-30 | ¥64m |
| —segment total | depreciation | 2021-10-01 → 2022-09-30 | ¥84m |
| —segment total | revenue | 2021-10-01 → 2022-09-30 | ¥634m |
| —segment total | revenue external | 2021-10-01 → 2022-09-30 | ¥634m |
| —segment total | segment assets | at 2022-09-30 | ¥790m |
| —segment total | segment profit | 2021-10-01 → 2022-09-30 | −¥815m |
| Reconciling Itemsreconciling | capex | 2020-10-01 → 2021-09-30 | ¥8m |
| Reconciling Itemsreconciling | depreciation | 2020-10-01 → 2021-09-30 | ¥23m |
| Reconciling Itemsreconciling | segment assets | at 2021-09-30 | ¥4.6bn |
| Reconciling Itemsreconciling | segment profit | 2020-10-01 → 2021-09-30 | −¥497m |
| Cellular And Tissue Based Product Businessreportable segment | capex | 2020-10-01 → 2021-09-30 | ¥7m |
| Cellular And Tissue Based Product Businessreportable segment | depreciation | 2020-10-01 → 2021-09-30 | ¥34m |
| Cellular And Tissue Based Product Businessreportable segment | revenue | 2020-10-01 → 2021-09-30 | ¥206,000 |
| Cellular And Tissue Based Product Businessreportable segment | revenue external | 2020-10-01 → 2021-09-30 | ¥206,000 |
| Cellular And Tissue Based Product Businessreportable segment | segment assets | at 2021-09-30 | ¥157m |
| Cellular And Tissue Based Product Businessreportable segment | segment profit | 2020-10-01 → 2021-09-30 | −¥451m |
| Contracted Cell Manufacturing Businessreportable segment | capex | 2020-10-01 → 2021-09-30 | ¥18m |
| Contracted Cell Manufacturing Businessreportable segment | depreciation | 2020-10-01 → 2021-09-30 | ¥58m |
| Contracted Cell Manufacturing Businessreportable segment | revenue | 2020-10-01 → 2021-09-30 | ¥683m |
| Contracted Cell Manufacturing Businessreportable segment | revenue external | 2020-10-01 → 2021-09-30 | ¥683m |
| Contracted Cell Manufacturing Businessreportable segment | segment assets | at 2021-09-30 | ¥666m |
| Contracted Cell Manufacturing Businessreportable segment | segment profit | 2020-10-01 → 2021-09-30 | −¥132m |
| —segment total | capex | 2020-10-01 → 2021-09-30 | ¥25m |
| —segment total | depreciation | 2020-10-01 → 2021-09-30 | ¥92m |
| —segment total | revenue | 2020-10-01 → 2021-09-30 | ¥683m |
| —segment total | revenue external | 2020-10-01 → 2021-09-30 | ¥683m |
| —segment total | segment assets | at 2021-09-30 | ¥824m |
| —segment total | segment profit | 2020-10-01 → 2021-09-30 | −¥583m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,053
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of issues whose number of shares increased shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | 1 | |
| Total acquisition cost for increased shares shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | 149009000 | JPY |
| Number of issues whose number of shares decreased shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | 1 | |
| Total sale amount for decreased shares shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | JPY |
| Number of issues whose number of shares decreased shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | |
| Total sale amount for decreased shares shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | JPY |
| Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | 3675000 | |
| Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row1Member | － | |
| Book value details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | 149009000 | JPY |
| Book value details of specified investment equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row1Member | － | JPY |
| Cash and deposits | Prior1YearInstant_NonConsolidatedMember | 4095689000 | JPY |
| Cash and deposits | CurrentYearInstant_NonConsolidatedMember | 4499095000 | JPY |
| Accounts receivable trade | Prior1YearInstant_NonConsolidatedMember | 219342000 | JPY |
| Accounts receivable trade | CurrentYearInstant_NonConsolidatedMember | 170996000 | JPY |
| Work in process | Prior1YearInstant_NonConsolidatedMember | 16511000 | JPY |
| Work in process | CurrentYearInstant_NonConsolidatedMember | 15732000 | JPY |
| Raw materials and supplies | Prior1YearInstant_NonConsolidatedMember | 25360000 | JPY |
| Raw materials and supplies | CurrentYearInstant_NonConsolidatedMember | 33787000 | JPY |
| Advance payments trade | Prior1YearInstant_NonConsolidatedMember | 50000 | JPY |
| Advance payments trade | CurrentYearInstant_NonConsolidatedMember | 956000 | JPY |
| Prepaid expenses | Prior1YearInstant_NonConsolidatedMember | 26429000 | JPY |
| Prepaid expenses | CurrentYearInstant_NonConsolidatedMember | 25243000 | JPY |
| Other ca | Prior1YearInstant_NonConsolidatedMember | 21470000 | JPY |
| Other ca | CurrentYearInstant_NonConsolidatedMember | 61659000 | JPY |
| Current assets | Prior1YearInstant_NonConsolidatedMember | 4404854000 | JPY |
| Current assets | CurrentYearInstant_NonConsolidatedMember | 4807470000 | JPY |
| Buildings net | Prior1YearInstant_NonConsolidatedMember | 557397000 | JPY |
| Buildings net | CurrentYearInstant_NonConsolidatedMember | 477475000 | JPY |
| Tools furniture and fixtures net | Prior1YearInstant_NonConsolidatedMember | 28413000 | JPY |
| Tools furniture and fixtures net | CurrentYearInstant_NonConsolidatedMember | 28059000 | JPY |
| Lease assets net ppe | Prior1YearInstant_NonConsolidatedMember | 13050000 | JPY |
| Lease assets net ppe | CurrentYearInstant_NonConsolidatedMember | 10169000 | JPY |
| Construction in progress | Prior1YearInstant_NonConsolidatedMember | 21633000 | JPY |
| Construction in progress | CurrentYearInstant_NonConsolidatedMember | 21482000 | JPY |
| Property plant and equipment | Prior1YearInstant_NonConsolidatedMember | 620494000 | JPY |
| Property plant and equipment | CurrentYearInstant_NonConsolidatedMember | 537186000 | JPY |
| Patent right | Prior1YearInstant_NonConsolidatedMember | － | JPY |
| Patent right | CurrentYearInstant_NonConsolidatedMember | 19791000 | JPY |
| Software | Prior1YearInstant_NonConsolidatedMember | 8690000 | JPY |
| Software | CurrentYearInstant_NonConsolidatedMember | 24406000 | JPY |
| Software in progress | Prior1YearInstant_NonConsolidatedMember | 38705000 | JPY |
| Software in progress | CurrentYearInstant_NonConsolidatedMember | 57489000 | JPY |
| Intangible assets | Prior1YearInstant_NonConsolidatedMember | 47395000 | JPY |
| Intangible assets | CurrentYearInstant_NonConsolidatedMember | 101687000 | JPY |
| Investment securities | Prior1YearInstant_NonConsolidatedMember | 165704000 | JPY |
| Investment securities | CurrentYearInstant_NonConsolidatedMember | 485357000 | JPY |
| Long term loans receivable | Prior1YearInstant_NonConsolidatedMember | 541250000 | JPY |
| Long term loans receivable | CurrentYearInstant_NonConsolidatedMember | 536250000 | JPY |
| Claims provable in bankruptcy claims provable in rehabilitation and other | Prior1YearInstant_NonConsolidatedMember | 28078000 | JPY |
| Claims provable in bankruptcy claims provable in rehabilitation and other | CurrentYearInstant_NonConsolidatedMember | 26878000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |